Things I read yesterday as part of my stock research activities.
New Orders Received
🟢 CMS Info Systems won a 10-year ₹1,000 Cr SBI contract to deliver integrated cash solutions for about 5,000 ATMs nationwide.
🟢 PTC Industries secured an ISRO Vikram Sarabhai Space Centre contract to process 40 tonnes titanium sponge into space-grade alloy ingots using Double VAR technology.
Partnerships & Acquisitions
🟢 Infosys and Cognition announced a strategic partnership to deploy Devin, Cognition’s AI software engineer, across Infosys’ internal teams and global client projects. This accelerates software development, automates engineering tasks, reduces technical debt, and boosts productivity, starting with financial services.
Core Business & Regulatory
🔴 India’s DGCA requested average fare data (economy/premium, Dec 1-15) from IndiGo, Air India, SpiceJet, and Akasa amid CCI antitrust probe into IndiGo’s alleged market abuse via price hikes after 4,500+ flight cancellations.
🟢 Panacea Biotec completed enrollment of 10,335 participants in Phase III trial of single-shot dengue vaccine DengiAll, moving the indigenous program toward final evaluation.
🟢 Gland Pharma received USFDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% OTC, expanding its ophthalmic product portfolio in the US.
Economy, IPO & Other
🟢 India’s Q2 FY2025-26 GDP grew 7.4% YoY up from 6.5% prior year, driven by robust industry (9.2%) and services (7.1%) growth.
🔴 SEBI found Bank of America shared material non-public info on a $180M block trade of Aditya Birla Sun Life AMC shares in 2024 and misled regulators.
🟢 WeWork India surpassed 100,000 members with 33.6% YoY growth from Dec 2024-2025, fueled by enterprise demand. Operating 68 centers across 8 cities, GCCs now drive 38% of revenue (up from 28%).
That’s it for today.
FINVEZTO.COM | Build Wealth, Systematically
At Finvezto Stock Research (Anand Ganapathy, SEBI Registered RA), we offer the following services. Do check out more details below.
Long Term Recommendations (Core Portfolio)
Medium Term Recommendations (Satellite Portfolio)
Short Term Strategies (Overlay Portfolio)
Toolkit for Stock Research (For DIY Investors & Traders)
Disclaimer: Anand Ganapathy K is a SEBI-registered Research Analyst with SEBI registration number INH000016630. This post is purely for learning purposes to understand more about the business. It does not recommend buying or selling stocks mentioned in this newsletter. Securities market investments carry market risks. Kindly review all related documents before investing.